Risk of developing drug abuse in administration of a new hexaazaisowurtzitane derivative-based analgesia (experimental study)
BYULLETEN SIBIRSKOY MEDITSINY(2022)
Abstract
The aim of the study was to assess the probability of developing withdrawal syndrome caused by discontinuation of 5-day administration of thiowurtzine with naloxone challenge test in the experiment. Materials and methods. The test sample of the analgesic "Thiowurtzine, capsule 120 mg" served as the study object. The active pharmaceutical ingredient is an organic, low molecular weight compound 4-(3,4-dibromothiophene carbonyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo [5,5,0,0(3,)(11),0(5,9)]dodecane that was first synthesized according to computer modeling results at the IPCET SB RAS (Biysk). The likelihood of developing physical dependence was explored by per os administration of thiowurtzine and the reference drug tramadol twice a day for 5 days as follows: 1) at 9 a.m. - thiowurtzine 50 mg / kg and tramadol 10 mg / kg, at 3 p.m. - thiowurtzine 50 mg / kg and tramadol 10 mg / kg; 2) at 9 a.m. - thiowurtzine 50 mg / kg and tramadol 10 mg / kg, at 3 p.m. - thiowurtzine 75 mg / kg and tramadol 15 mg / kg; 3) at 9 a.m. - thiowurtzine 75 mg / kg and tramadol 15 mg / kg, at 3 p.m. - thiowurtzine 75 mg / kg and tramadol 15 mg / kg; 4) at 9 a.m. - thiowurtzine 100 mg / kg and tramadol 20 mg / kg, at 3 p.m. - thiowurtzine 100 mg / kg and tramadol 20 mg / kg; 5) at 9 a.m. - thiowurtzine 100 mg / kg and tramadol 20 mg / kg, at 3 p.m. - naloxone 10 mg / kg subcutaneously. In all the groups, the intensity of the withdrawal syndrome was studied by specific features in outbred male CD1 mice. During one hour following the naloxone injection, health of mice was assessed according to dominant abstinence components and recessive traits of mild withdrawal syndrome. Two hours after the naloxone injection, the number of mice with negative body weight gain was determined. 24 hours after discontinuation of test compound administration, the open-field test was used to determine the impact on animal behavioral patterns (horizontal and vertical motor and exploratory activity, emotionality and its vegetative manifestations). The hot plate test was carried out to measure the analgesic activity (55 degrees). The criterion of the withdrawal syndrome severity was a decrease in the number of jumping reactions, changes in the general condition of the animals, stimulation of motor activity, manifestations of hyperalgesia, and a decrease in body weight. Results. No dominant abstinence components and recessive signs of withdrawal syndrome were detected in animals from the thiowurtzine groups. The data obtained in the study (orientation and exploratory behavior, motor activity, emotionality and its vegetative manifestations, grooming, etc.) allow to conclude that thiowurtzine causes no physical dependence in animals after discontinuation of its 5-day administration with naloxone challenge test, as opposed to the reference drug naloxone. A positive disinhibition effect of this analgesic was revealed due to the activated orientation and exploratory behavior (stress caused by the new environment) in the conditions of the open-field test. The animals showed no manifestations of hyperalgesia in the hot plate test. The animals treated with thiowurtzine did not demonstrate any changes in the body weight. Conclusion. The obtained results prove that thiowurtzine is a non-narcotic analgesic. It evokes no side effects typical of opioid analgesics (tramadol), including development of physical dependence and withdrawal syndrome following naloxone challenge test. Previous in vivo and in silico studies (docking, molecular modeling, molecular dynamics simulation) on the multi-target mechanism of thiowurtzine explain the absence of its morphine-like effect by the fact that the major targets of the analgesic are TRPA1 receptors and voltage-gated Ca" channels. With a high degree of probability, the conclusions made herein predict no drug abuse development when thiowurtzine is used in the clinical setting. Absence of ulcerotoxicity found earlier will enable to administer thiowurtzine in long-term cycles for chronic pain syndrome.
MoreTranslated text
Key words
hexaazaisowurtzitane, thiowurtzine, analgesic activity, withdrawal syndrome, physical dependence, naloxone, tramadol
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined